Vinay Prasad has returned to lead the FDA's Center for Biologics Evaluation and Research (CBER) shortly after his abrupt departure amidst tensions related to gene therapy regulation and public controversy. The Health and Human Services spokesperson confirmed Prasad's reassignment at the FDA's request, marking a swift turnaround for the high-profile official responsible for overseeing vaccines and gene therapies. This development reflects ongoing challenges in FDA leadership and biotherapeutic oversight.